MX2014014813A - Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. - Google Patents
Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.Info
- Publication number
- MX2014014813A MX2014014813A MX2014014813A MX2014014813A MX2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A MX 2014014813 A MX2014014813 A MX 2014014813A
- Authority
- MX
- Mexico
- Prior art keywords
- sleep disorders
- ghrelin receptor
- treating sleep
- receptor inverse
- antagonists
- Prior art date
Links
- 102000000393 Ghrelin Receptors Human genes 0.000 title abstract 3
- 108010016122 Ghrelin Receptors Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 3
- 208000019116 sleep disease Diseases 0.000 title abstract 3
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655177P | 2012-06-04 | 2012-06-04 | |
| US201361812416P | 2013-04-16 | 2013-04-16 | |
| PCT/IB2013/054177 WO2013182933A1 (en) | 2012-06-04 | 2013-05-21 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014014813A true MX2014014813A (es) | 2015-02-12 |
Family
ID=48700662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014014813A MX2014014813A (es) | 2012-06-04 | 2013-05-21 | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9370516B2 (https=) |
| EP (1) | EP2854856B1 (https=) |
| JP (1) | JP6165852B2 (https=) |
| KR (1) | KR101708989B1 (https=) |
| CN (1) | CN104334193A (https=) |
| AU (1) | AU2013273263B2 (https=) |
| BR (1) | BR112014029577A2 (https=) |
| CA (1) | CA2874196C (https=) |
| ES (1) | ES2716303T3 (https=) |
| HK (1) | HK1202459A1 (https=) |
| IL (1) | IL235883A0 (https=) |
| MX (1) | MX2014014813A (https=) |
| RU (1) | RU2600895C2 (https=) |
| SG (1) | SG11201407387UA (https=) |
| WO (1) | WO2013182933A1 (https=) |
| ZA (1) | ZA201408672B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175272A (zh) * | 2015-08-31 | 2015-12-23 | 吴玲 | 制备r-5-溴-1-氨基茚满的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| JP4717444B2 (ja) * | 2002-12-20 | 2011-07-06 | ザ マクレーン ホスピタル コーポレーション | 睡眠／覚醒サイクルの正規化のための化合物 |
| US20050171132A1 (en) * | 2003-09-26 | 2005-08-04 | Zhili Xin | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists |
| US20090149512A1 (en) * | 2004-05-14 | 2009-06-11 | Novo Nordisk A/S | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases |
| US20090253673A1 (en) * | 2006-07-12 | 2009-10-08 | Min Ge | Substituted Pyrazoles as Ghrelin Receptor Antagonists |
| US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
| DK2547679T3 (en) | 2010-03-19 | 2016-01-11 | Pfizer | 2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor |
-
2013
- 2013-05-21 BR BR112014029577A patent/BR112014029577A2/pt active Search and Examination
- 2013-05-21 ES ES13732257T patent/ES2716303T3/es active Active
- 2013-05-21 EP EP13732257.4A patent/EP2854856B1/en not_active Not-in-force
- 2013-05-21 WO PCT/IB2013/054177 patent/WO2013182933A1/en not_active Ceased
- 2013-05-21 US US14/398,800 patent/US9370516B2/en active Active
- 2013-05-21 KR KR1020147034009A patent/KR101708989B1/ko not_active Expired - Fee Related
- 2013-05-21 AU AU2013273263A patent/AU2013273263B2/en not_active Ceased
- 2013-05-21 SG SG11201407387UA patent/SG11201407387UA/en unknown
- 2013-05-21 CA CA2874196A patent/CA2874196C/en not_active Expired - Fee Related
- 2013-05-21 HK HK15103243.2A patent/HK1202459A1/xx unknown
- 2013-05-21 MX MX2014014813A patent/MX2014014813A/es unknown
- 2013-05-21 JP JP2015515606A patent/JP6165852B2/ja not_active Expired - Fee Related
- 2013-05-21 RU RU2014146109/15A patent/RU2600895C2/ru not_active IP Right Cessation
- 2013-05-21 CN CN201380029429.7A patent/CN104334193A/zh active Pending
-
2014
- 2014-11-24 IL IL235883A patent/IL235883A0/en unknown
- 2014-11-25 ZA ZA2014/08672A patent/ZA201408672B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104334193A (zh) | 2015-02-04 |
| KR20150013236A (ko) | 2015-02-04 |
| EP2854856A1 (en) | 2015-04-08 |
| BR112014029577A2 (pt) | 2017-06-27 |
| AU2013273263A1 (en) | 2014-11-27 |
| KR101708989B1 (ko) | 2017-02-21 |
| ZA201408672B (en) | 2016-09-28 |
| WO2013182933A1 (en) | 2013-12-12 |
| CA2874196C (en) | 2016-12-06 |
| ES2716303T3 (es) | 2019-06-11 |
| US20150119381A1 (en) | 2015-04-30 |
| JP6165852B2 (ja) | 2017-07-19 |
| HK1202459A1 (en) | 2015-10-02 |
| RU2014146109A (ru) | 2016-07-27 |
| IL235883A0 (en) | 2015-01-29 |
| EP2854856B1 (en) | 2019-01-23 |
| JP2015518876A (ja) | 2015-07-06 |
| US9370516B2 (en) | 2016-06-21 |
| AU2013273263B2 (en) | 2017-08-24 |
| RU2600895C2 (ru) | 2016-10-27 |
| SG11201407387UA (en) | 2014-12-30 |
| CA2874196A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| JO3078B1 (ar) | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة | |
| MX2015002292A (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r. | |
| MX369576B (es) | Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4. | |
| PH12015501596B1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX346559B (es) | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico. | |
| WO2014066799A3 (en) | Modulators of resistant androgen receptor | |
| MX2015002005A (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
| MX345656B (es) | (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7. | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| PH12014501390A1 (en) | Novel therapeutic use of p75 receptor antagonists | |
| MX2014014813A (es) | Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño. | |
| IN2014DN09359A (https=) | ||
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. |